Business Wire

CGTN

Share
CGTN:Why Did Xi Jinping Make Fujian His First Stop After Five-year Plan Approval?

As China's latest medium and long-term economic and social development plan was just approved at the country's top legislature, President Xi Jinping has left Beijing for his first inspection trip to east China's Fujian Province after the Two Sessions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210323006017/en/

Xi's visits to an ecological tea garden and the Wuyishan National Park during the inspection show the importance he attaches to green, ecological development, which was also stressed in China's road map for development for the next five years and beyond.

Wuyi Mountain and ecological protection

Standing in the suburbs of Wuyishan City, Mount Wuyi entered UNESCO's list of World Heritage Sites in 1999. It covers an area of over 630 square kilometers and numerous types of tea are produced there.

Visiting mountains is usually arranged in Xi's inspection tours as construction of ecological civilization has always been stressed by the president.

In April 2020, Xi's first stop was also to visit the mountains. He went directly to the Qinling Mountains during his inspection in northwest China's Shaanxi Province to learn about ecological protection, urging officials to be guardians of ecological environment.

In August 2019, he went to northwest China's Gansu Province and visited the Qilian Mountains, underlining ecological protection as a national strategy.

On Monday, during his visit to the Wuyishan National Park, he encountered a group of tourists. "You can enjoy the mountain scenery in Wuyishan and enjoy the seascape in Xiamen City," he told the group.

Xi also visited the park's intelligent management center, where all the weather monitoring and services for biological resources within the park are conducted.

During the just-concluded Two Sessions, he said top-level design and comprehensive measures are needed to protect the ecosystems in mountains, rivers, forests, farmlands, lakes, grasslands and deserts.

Tea industry and rural vitalization

"In the past, the tea industry was a pillar in your fight against poverty, and it should become a pillar industry of rural vitalization in the future," Xi said on Monday at the tea garden.

He called for efforts to better cultivate a vibrant tea industry that takes advantage of Mount Wuyi's long history of tea culture, suitable climate, rich tea resources and the support of science and technology.

Shaking off poverty is not the finish line but the starting line of a new life and new endeavor, Xi said in February after announcing that China has secured a "complete victory" in its fight against poverty, urging efforts to effectively integrate the consolidation of poverty alleviation achievements and rural vitalization.

China detailed plans to fully promote the strategy of rural vitalization in the Chinese leadership's proposals for formulating the 14th Five-Year Plan (2021-2025) for National Economic and Social Development and the Long-Range Objectives Through the Year 2035.

Under this development blueprint, the country will push the development of industries with distinctive rural characteristics, cultivate new industries and modes of business, and encourage entrepreneurship and innovation in rural areas.

During his stop at the tea garden, Xi was pleased when hearing that the quality of tea was greatly improved through ecological planting in recent years, under the guidance of the team of technology commissioners.

Agricultural talents, also called "technological commissioners," was an idea introduced by Xi, the then governor to Fujian Province in a 2002 article, which called for bonding officials and farmers.

The president has stressed the role of science and technology in poverty alleviation and rural revitalization many times, calling for efforts to promote science and technological innovation in agriculture to support all-around rural revitalization.

During the inspection, Xi also visited a park dedicated to Zhu Xi, a renowned Chinese philosopher in the 12th century, in Nanping City on Monday afternoon, learning about local efforts to pass on traditional culture.

https://news.cgtn.com/news/2021-03-23/Xi-Jinping-makes-Fujian-his-first-stop-after-Five-Year-Plan-approval-YRH8REcXW8/index.html

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Nexo Becomes First-Ever Title Partner of the U.S. ATP 500 Dallas Open in Multi-Year Deal13.1.2026 16:30:00 CET | Press release

The agreement builds on Nexo’s long-term approach to partnerships with established global sports institutions. Nexo, the digital assets wealth platform, has been named the U.S. ATP 500 Dallas Open’s first-ever Title Partner under a multi-year agreement beginning in 2026, as the company advances its long-term brand strategy through leading global sports properties. The partnership was unveiled in Dallas alongside the debut of the Nexo Dallas Open brand and the resurfacing of two public tennis courts in North Texas. As one of only two ATP 500 tournaments in the U.S. and the country’s sole indoor ATP Tour championship, the Dallas Open places Nexo among a limited group of ATP 500 title partners. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260113901822/en/ The Nexo Dallas Open “This partnership with Nexo represents a transformative milestone for the Dallas Open,” said Tournament Director Peter Lebedevs. “Securing a title spons

Blue Matter Establishes New Capabilities in Biopharma Research & Development Led by Partner, Tara Austraat-Churik13.1.2026 15:01:00 CET | Press release

Blue Matter is pleased to announce that it has established a practice area dedicated to serving clients in biopharmaceutical Research & Development (R&D). The practice is led by Tara Austraat-Churik, a Partner who joined the firm in September 2025. Tara Austraat-Churik has been serving life science clients for more than 20 years. Her areas of expertise include strategy development and implementation, operating model and organizational design, and process optimization in R&D and Medical Affairs. Prior to joining Blue Matter, she served as Managing Director in R&D, Health, Science, and Wellness at EY. She has a robust background in consulting, which also includes roles at Booz Allen Hamilton, Navitas, WPP, and IBM. She holds a BA and MA from the University of Notre Dame and an MSc in Translational Medicine from the University of Edinburgh. The R&D practice, according to Austraat-Churik, exists to help biopharma companies simplify and accelerate the pathway to market. She adds, “R&D organ

Wasabi Raises $70M in New Equity to Power the Next Era of Data Infrastructure13.1.2026 15:00:00 CET | Press release

At a $1.8 billion valuation, backed by L2 Point and Pure Storage, the company scales AI-first cloud storage to meet the explosive demands of modern data Wasabi Technologies, the Hot Cloud Storage company, today announced a $70 million equity funding round led by L2 Point Management with participation from Pure Storage and existing investors including Fidelity Management & Research Company. The new round values Wasabi at $1.8 billion and brings the company’s total funding to over $600 million. The capital will be used to accelerate Wasabi’s expansion into AI infrastructure, broaden its global footprint, and enhance its product portfolio to meet the growing data demands of enterprises and AI developers worldwide. “We’re ushering in the next generation of cloud storage, powering data-intensive workloads like generative AI and autonomous systems,” said David Friend, co-founder and CEO of Wasabi Technologies. “This funding underscores Wasabi’s strong market position and continued growth as

HumanX Amsterdam Reveals First 100 Speakers, Bringing Global AI Powerhouses to Europe13.1.2026 14:00:00 CET | Press release

Anton Osika (Lovable), May Habib (Writer), Jan Oberhauser (n8n) & Eléonore Crespo (Pigment) headline a diverse lineup spanning AI innovation and enterprise adoption HumanX, the global AI summit for executives and innovators, today unveiled its first 100 speakers and opened registration for HumanX Amsterdam, taking place 22–24 September 2026 at The RAI. Built by the team behind Money20/20, Shoptalk, and HLTH, HumanX Amsterdam brings the proven formula of its #1 U.S. flagship event and ecosystem gathering to Europe. The event convenes over 2,500 senior leaders focused on moving beyond the hype to drive practical, responsible AI implementation across industries. Speakers Leading the Conversation The first 100 speakers include AI company founders such as Anton Osika (Lovable), Jan Oberhauser (n8n), May Habib (Writer), Arvind Jain (Glean), and Jarek Kutylowski (DeepL), alongside executives scaling AI in the enterprise, including Clay Bavor (Sierra), Des Traynor (Intercom), and Eléonore Cres

GARDP and Debiopharm Partner to Advance Development of Novel Gonorrhea Drug13.1.2026 14:00:00 CET | Press release

The GARDP Foundation (known as GARDP) and the privately-owned, global biopharmaceutical company Debiopharm today announced that they have entered into a collaboration and license agreement to pursue the development of Debio1453, a novel, first-in-class antibiotic targeting Neisseria gonorrhoeae. With 82 million new cases each year, and the continued spread of multidrug-resistant N. gonorrhoeae strains, gonorrhea represents a global health crisis. This new partnership will help ensure that gonorrhea continues to be a treatable disease and will alleviate the risk of the emergence of future resistance, by ensuring that the antibiotic pipeline continues to be replenished. Gonorrhea caused by N. gonorrhoeae is currently in danger of becoming untreatable because of antimicrobial resistance (AMR). Having developed resistance to almost all antibiotics used to treat it, only one last recommended treatment, ceftriaxone, remains effective, and now we are seeing a growing number of cases that are

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye